Dr. Fred Schumacher is Associate Professor in the Department of Population and Quantitative Health Sciences and Faculty in the Cleveland Institute for Computational Biology, both at Case Western Reserve University. Dr. Schumacher is also Co-Leader of the Cancer Prevention Control & Population Research Program as part of the Case Comprehensive Cancer Center. His primary research focus is on cancer, particularly prostate cancer. As an investigator and leader in several major international consortium, Dr. Schumacher has
- Identified multiple novel genomic regions associated with prostate, testicular and breast cancer, representing discoveries based on incorporating genome-wide association studies (GWAS) with cancer epidemiology
- Expanded the use of GWAS through combined studies of varying design, providing the power to evaluate candidate gene pathways, incorporate related biomarkers, and assess cancer sub-types
- Explored the potential biological overlap of complex traits and conditions (such as diabetes) with cancer, providing a better understanding of the cancer initiation process and highlighting several areas for potential disease risk reduction.
- Developed and implemented polygenic risk scores to improve screening modalities and treatment paradigms
- Yarmolinsky, J, Bouras, E, Constantinescu, A, Burrows, K, Bull, CJ, Vincent, EE, Martin, RM, Dimopoulou, O, Lewis, SJ, Moreno, V et al.. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis. Diabetologia 2023; : . PubMed PMID:37171501 .
- Shu, TD, Schumacher, FR, Conroy, B, Ponsky, L, Mahran, A, Bukavina, L, Calaway, A, Markt, SC. Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database. Cancer Causes Control 2023; 34 (6): 521-531. PubMed PMID:36882598 .
- Thomas, M, Su, YR, Rosenthal, EA, Sakoda, LC, Schmit, SL, Timofeeva, MN, Chen, Z, Fernandez-Rozadilla, C, Law, PJ, Murphy, N et al.. Combining Asian-European Genome-Wide Association Studies of Colorectal Cancer Improves Risk Prediction Across Race and Ethnicity. medRxiv 2023; : . PubMed PMID:36789420 PubMed Central PMC9928144.
- Koroukian, SM, Booker, BD, Vu, L, Schumacher, FR, Rose, J, Cooper, GS, Selfridge, JE, Markt, SC. Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer. JAMA Netw Open 2023; 6 (1): e2250030. PubMed PMID:36656585 PubMed Central PMC9857024.
- Fu, C, Ngo, J, Zhang, S, Lu, L, Miron, A, Schafer, S, Gage, FH, Jin, F, Schumacher, FR, Wynshaw-Boris, A et al.. Novel correlative analysis identifies multiple genomic variations impacting ASD with macrocephaly. Hum Mol Genet 2023; 32 (10): 1589-1606. PubMed PMID:36519762 PubMed Central PMC10162433.
- McManus, JM, Vargas, R, Bazeley, PS, Schumacher, FR, Sharifi, N. Association Between Adrenal-Restrictive HSD3B1 Inheritance and Hormone-Independent Subtypes of Endometrial and Breast Cancer. JNCI Cancer Spectr 2022; 6 (5): . PubMed PMID:35947687 PubMed Central PMC9475354.
- Arenas-Gallo, C, Owiredu, J, Weinstein, I, Lewicki, P, Basourakos, SP, Vince, R Jr, Al Hussein Al Awamlh, B, Schumacher, FR, Spratt, DE, Barbieri, CE et al.. Race and prostate cancer: genomic landscape. Nat Rev Urol 2022; 19 (9): 547-561. PubMed PMID:35945369 .
- Isali, I, McClellan, P, Wong, TR, Sun, C, Stout, AC, Schumacher, FR, Markt, S, Wilfred Wu, CH, Penney, KL, El-Nashar, S et al.. A systematic review and in silico study of potential genetic markers implicated in cases of overactive bladder. Am J Obstet Gynecol 2023; 228 (1): 36-47.e3. PubMed PMID:35932882 PubMed Central PMC10152473.
- Miller, AK, Gordon, JC, Curtis, JW, Ajayakumar, J, Schumacher, FR, Avril, S. The Geographic Context of Racial Disparities in Aggressive Endometrial Cancer Subtypes: Integrating Social and Environmental Aspects to Discern Biological Outcomes. Int J Environ Res Public Health 2022; 19 (14): . PubMed PMID:35886465 PubMed Central PMC9320863.
- Markt, SC, Booker, BD, Bensken, W, Schiltz, NK, Schumacher, FR, Rose, J, Cooper, G, Selfridge, JE, Koroukian, SM. Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer. Cancer Med 2023; 12 (2): 1850-1859. PubMed PMID:35837788 PubMed Central PMC9883565.